August 11th, 2025

Dear

We are pleased to share that Zevra Therapeutics announced the filing of our Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for arimoclomol for the treatment of Niemann Pick C. This marks a major milestone in the Company's journey toward making MIPLYFFA foundational therapy available to patients with NPC across Europe.

The EMA will review the application under the centralized marketing authorization procedure. If a marketing authorization is granted by the European Commission, the authorization is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

This milestone would not have been possible without the enormous efforts, support and participation of patients, their families and caregivers, and you the investigators and treating physicians.

We look forward to continuing our work with you and the NPC community.
https://investors.zevra.com/news-releases/news-release-details/zevra-therapeutics-submits-marketing-authorization-application
Please find a link to the press release
For further information, please contact medical affairs at: info@zevra.com

Kind Regards,

Adrian Quartel
MD, CMO

and

Christine í Dali,
MD, VP Clinical Science.